# SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies

Source: https://onco.cc/key-papers/paper-cd19-dlbcl-clin-cancer-res-2011/  
OnCo record `paper-cd19-dlbcl-clin-cancer-res-2011` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Review on CD19 in Diffuse large B-cell lymphoma, in Clinical Cancer Research (2011), one of the most cited Europe PMC records with CD19 in its title.

## Summary

SAR3419 is a novel anti-CD19 humanized monoclonal antibody conjugated to a maytansine derivate through a cleavable linker for the treatment of B-cell malignancies. SAR3419 combines the strengths of a high-potency tubulin inhibitor and the exquisite B-cell selectivity of an anti-CD19 antibody. The internalization and processing of SAR3419, following its binding at the surface of CD19-positive human lymphoma cell lines and xenograft models, release active metabolites that trigger cell-cycle arrest and apoptosis, leading to cell death and tumor regression. SAR3419 has also been shown to be active in different lymphoma xenograft models, including aggressive diffuse large B-cell lymphoma, resulting in complete regressions and tumor-free survival. In these models, the activity of SAR3419 compared favorably with rituximab and lymphoma standard of care chemotherapy. Two phase I trials with 2 different schedules of SAR3419 as a single agent were conducted in refractory/relapsed B-cell non-Hodgkin lymphoma. Activity was reported in both schedules, in heavily pretreated patients of both follicular and diffuse large B-cell lymphoma subtypes, with a notable lack of significant hematological toxicity, validating SAR3419 as an effective antibody-drug conjugate and opening opportunities in the future. Numerous B-cell-specific anti-CD19 biologics are available to treat B-cell non-Hodgkin lymphoma, and early phase I results obtained with SAR3419 suggest that it is a promising candidate for further development in this disease. In addition, thanks to the broad expression of CD19, SAR3419 may provide treatment options for B-cell leukemias that are often CD20-negative.

Indexed on Europe PMC as PubMed record 22003072 (DOI 10.1158/1078-0432.ccr-11-0485). Its title names CD19 and its text names Diffuse large B-cell lymphoma; PubMed types it as a review (Review). It was matched automatically to the idea "In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma" and no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: Clinical Cancer Research
- Year: 2011
- DOI: 10.1158/1078-0432.ccr-11-0485
- Authors: Blanc V, Bousseau A, Caron A, et al.
- What it means: One of the most cited reviews Europe PMC returns for CD19 in Diffuse large B-cell lymphoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
- Caveats: Matched by CD19 in the title and Diffuse large B-cell lymphoma in the title or abstract of the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.; A review summarises other studies; the primary reports it cites are the evidence.

## Sources

- Clin Cancer Res 2011: https://doi.org/10.1158/1078-0432.ccr-11-0485
- PubMed: https://pubmed.ncbi.nlm.nih.gov/22003072/
- Europe PMC: https://europepmc.org/article/MED/22003072

## Connected records

- journals: [Clinical Cancer Research](https://onco.cc/journals/clinical-cancer-research/)
- ideas: [In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma](https://onco.cc/ideas/idea-reg-in-vivo-cart-off-the-shelf-vial/), [Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route](https://onco.cc/ideas/idea-reg-non-viral-cart-manufacturing/)

---
JSON: https://onco.cc/api/v1/entities/paper-cd19-dlbcl-clin-cancer-res-2011.json